Business
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501. There has been heightened industry activity in the IL-6 pathway space, underscored by Novartis’ recent acquisition of Tourmaline Bio for approximately $1.4 billion. Tiziana will pursue non-dilutive funding strategies for the development of TZLS-501 while conti
About this update from Tiziana Life Sciences Ltd
[{"type":"image","alt":"Tiziana Life Sciences Ltd.","displaySize":"","headline":null,"caption":"Tiziana Life Sciences Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":264,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/08f5d705b5df39888a6496fd7522f947"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3k64r3yQgq2ENSiAhwIMCA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/08f5d705b5df39888a6496fd7522f947","width":264,"height":60}},"lazy":false},{"type":"text","content":"BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501. There has been heightened industry activity in the IL-6 pathway space, underscored by Novartis’ recent acquisition of Tourmaline Bio for approximately $1.4 billion. Tiziana will pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance intranasal foralumab as its lead program.","length":558,"tagName":"p"},{"type":"text","content":"TZLS-501 is a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody (mAb) targeting both the membrane-bound and soluble forms of IL-6R. This dual mechanism of action not only blocks IL-6R signaling but also reduces circulating IL-6 cytokines, which are recognized drivers of inflammation, lung damage, and chronic fibrosis. Tiziana sees potential to develop TZLS-501 as a monotherapy, or in combination with its lead candidate, foralumab, as well as with other anti-inflammatory and anti-infective agents.","length":512,"tagName":"p"},{"type":"text","content":"The recent acquisition by Novartis further validates the importance of IL-6 therapeutics. Tiziana believes this an opportune time for the parallel advancement of TZLS-501. Accordingly, Tiziana will pursue development of TZLS-501, while not diverting resources or focus from ongoing clinical trials with foralumab.","length":313,"tagName":"p"},{"type":"text","content":"Excessive IL-6 signaling plays a central role in multiple diseases, including rheumatoid arthritis (RA), acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF), systemic lupus erythematosus, and various cancers. By reducing both receptor-mediated signa...